Liver and biliary tract cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 92
• PD-L1 51
• TP53 3
• PI3K 0
• mTOR 1
• AKT 0
• STAT3 1
• VEGF 20
• FGFR 22
• GPC3 38
• CTNNB1 5
• YAP 0
• HER2 28
• MAPK 0
• NRF2 0
• HIF-1 0
• PPAR 0
• ERK 0
• AMPK 0
• EGFR 8
• STING 0
• CTLA-4 20
• MYC 0
• IDH 6
• JAK 0
• JNK 0
• PTEN 0
• GPX4 0
• KRAS 8
• BCL-2 0
• HSP90 0
• IL-6 1
• PSMA 8
• MET 1
• GLP-1 1
• BRAF 3
• EZH2 0
• NLRP3 0
• CLDN18 10
• MEK 0
• B7-H3 5
• COX-2 0
• HDAC 0
• CXCR4 0
• HMGB1 0
• METTL3 0
• SIRT1 0
• TLR4 0
• MMP-9 0
• TNF 0
• PARP 2
• PCSK9 0
• TIGIT 2
• TIM-3 1
• CDK4/6 0
• IL-17 0
• RAS 2
• SGLT2 0
• CD47 0
• IL-15 2

24 of 48+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell Therapy

  March Biosciences Inc· Houston, United States· US$399,003 awarded in fiscal year 2026· until Aug 2027

• NIH NIDDK · R01

  Stakeholder Engagement and Modeling for Adoption of a Novel Cirrhosis Detection Algorithm

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$810,994 awarded in fiscal year 2026· until Jun 2030

• NIH NCI · R01

  Assessment of sound waves from liver vessels via artificial intelligence to detect liver cancer

  University of Minnesota· Minneapolis, United States· US$18,735 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R41

  MUSIC: Multiplexed siRNA and CRISPR in an LNP to knockout cancer

  Jumble Therapeutics, Inc· Cambridge, United States· US$395,652 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · K08

  Metabolic Imaging to Enable Targeted Therapy for Hepatocellular Carcinoma

  University of Pennsylvania· Philadelphia, United States· US$296,232 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Glutaminase Isoenzymes: Gatekeepers of Bioenergetics, Immunity, and Tumor Microenvironment in Diabetes-Induced Hepatocellular Carcinoma (IRM)

  Fundacion Para la Investigacion de Malaga En Biomedicina y Salud· Malaga, Spain· EU contribution €209,915· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  Decoding Neural Circuits in Cholangiocarcinoma (LIVER-CIRCUITS)

  Technische Universitaet Dresden· Dresden, Germany· EU contribution €1,500,000· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling Malignant Cholangiocyte Subpopulations that Drive Chemoresistance in Cholangiocarcinoma (RESIST-CCA)

  Humanitas Mirasole Spa· Rozzano (Mi), Italy· EU contribution €193,643· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Multiscale 3D virtual histology with non-destructive x-rays (XHIST)

  Danmarks Tekniske Universitet· Kongens Lyngby, Denmark· EU contribution €150,000· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Mechano-metabOlic Responsive nanoPlatform for HeterogEnous tUmor Suppression (MORPHEUS)

  Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe· Valencia, Spain· EU contribution €2,499,745· until Aug 2031

  The disease is named only in the funder's project summary, not in the title.

10 of 875 running projects, newest first. Listed amounts together: US$477.7m + €133.0m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

  NCT07365839· Virginia Commonwealth University· Updated 14 Sept 2026

  “The study was withdrawn because the pharmaceutical company decided not to pursue this combination of drugs following negative data in another indication.”Registry text, quoted unchanged. Source

• Terminated

  Study of PF-07265807 in Participants With Metastatic Solid Tumors.

  NCT04458259· Pfizer· Updated 4 Jun 2026

  “Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Updated 12 Jan 2026

  “Business Decision”Registry text, quoted unchanged. Source

• Withdrawn

  Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures

  NCT06084689· Institut Bergonié· Updated 2 Sept 2025

  “Discontinuation of molecule development”Registry text, quoted unchanged. Source

• Withdrawn

  Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC

  NCT06361758· Shanghai Zhongshan Hospital· Updated 23 May 2025

  “The PI has initiated a global multicenter Phase II clinical trial in the same direction, conducted by Akesobio.”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

  NCT05757492· Coherus Oncology, Inc.· Updated 1 May 2025

  “The study was terminated for strategic reasons (not for safety concerns)”Registry text, quoted unchanged. Source

• Terminated

  Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT

  NCT04709380· Cancer Institute and Hospital, Chinese Academy of Medical Sciences· Updated 26 Feb 2025

  “IDMC recommended to terminate the study since Interim analysis showed that the experimental group had significant superiority over the control group in TTP and OS (p\<0.001), meeting the predefined interim analysis endpoints in the study protocol.”Registry text, quoted unchanged. Source

• Withdrawn

  A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

  NCT04465734· Shanghai Henlius Biotech· Updated 5 May 2022

  “The trial used sorafenib as a control drug. It's not suitable now(after the A+T has been approved).The sponsor terminated the trial.”Registry text, quoted unchanged. Source

• Withdrawn

  GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC

  NCT05019677· Fudan University· Updated 4 Apr 2022

  “Repeat registration”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  NCT06066138· National Cancer Institute (NCI)· Source

• MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

  NCT05007106· Merck Sharp & Dohme LLC· Source

• Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer

  NCT07710885· Taiho Pharmaceutical Co., Ltd.· Source

• Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

  NCT04740307· Merck Sharp & Dohme LLC· Source

• Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma

  NCT07646717· Tianjin Medical University Cancer Institute and Hospital· Source

• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Merck Sharp & Dohme LLC· Source

• Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Merck Sharp & Dohme LLC· Source

• Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

  NCT04924062· Merck Sharp & Dohme LLC· Source

• Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· Merck Sharp & Dohme LLC· Source

• A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC

  NCT07432568· Tianjin Medical University Cancer Institute and Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 109
• Organoids 40
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 34
• Gene Expression Profiling 281
• Sequence Analysis, RNA 20
• Whole Genome Sequencing 9
• Exome Sequencing 19
• Proteomics 119
• Metabolomics 73
• Mass Spectrometry 23
• Flow Cytometry 66
• Immunohistochemistry 125
• Liquid Biopsy 34
• Circulating Tumor DNA 42
• Xenograft Model Antitumor Assays 443
• Positron-Emission Tomography 35
• Magnetic Resonance Imaging 376
• Machine Learning 199
• Deep Learning 114
• Cohort Studies 184
• Genome-Wide Association Study 42

See which targets of this disease your abstract mentions, and go to the people working on them.